Jack in the Box heads into its May 13 earnings report with short sellers at their most aggressive in years, a stock down 12% on the week, and every analyst on the Street cutting targets rather than upgrading.
The short interest picture is the defining story here. Shorts now hold 45.3% of the free float — up sharply from 33% in mid-March after a step-change jump around April 10, when an estimated 900,000 shares of new short positioning appeared almost overnight. The past month alone saw a 37% increase in shares sold short, cementing JACK as one of the most heavily shorted names in the restaurant sector. The ORTEX short score reflects that conviction: 77.7 out of 100, a level that places the stock in the fourth percentile for short score ranking across the entire universe. Days to cover runs at 7.7 per the latest FINRA data, so unwinding this position is not a quick exercise.
The borrow market tells a more nuanced story. Availability has tightened meaningfully — currently around 66% of short interest, down from highs near 74% at the start of April and sitting well below the 200% threshold that characterises a normal lending environment. That range of 56–68% seen throughout April signals the pool is genuinely constrained, with roughly two shares available for every three already lent out. Cost to borrow has actually eased, falling 27% over the past month to just over 1%, which suggests no acute squeeze in the mechanics yet — shorts are crowded, but financing remains cheap. Options positioning has flipped sharply in the other direction. The put/call ratio has collapsed from above 1.3 in late March to 0.86, nearly 1.7 standard deviations below its 20-day average. That is one of the most bullish options readings of the past year for this stock — a notable divergence from the positioning in the lending market.
The Street has delivered an unambiguous verdict over the past month: every single recent analyst action has been a target cut, with no upgrades and no new bullish initiations. Morgan Stanley's John Glass trimmed to $15 on April 21. Citigroup's Jon Tower followed suit on April 29, also cutting to $15 from $24. TD Cowen moved to $12, Mizuho to $11, and Stifel to $10. The consensus mean sits near $21.70, but that figure now looks stale against a $12.30 stock price — the most recent cluster of targets from bellwether firms is pointing directly at or below current levels. Goldman Sachs maintains a Sell. The bear case is well-articulated: same-store sales fell 7.4% last quarter, a further 6.7% decline is pencilled in for Q1 FY26, and EPS estimates have been slashed to $3.10 for FY26, well below prior expectations. The bull case rests on management's reaffirmed EBITDA guidance of $225–$240 million for the full year and the expectation of a return to positive same-store sales in the second half — a recovery thesis that analysts are currently unwilling to price in.
The earnings reaction history adds another layer of caution. The February 27 print produced a 10.8% one-day drop and a 16.1% five-day decline. Before that, a February 18 event drove a 15.6% single-day fall and a 20.9% five-day loss. Two consecutive quarters of double-digit post-earnings declines establish a pattern: this stock has consistently punished longs at results time. With an ORTEX combined score of 77.6 and EPS momentum ranks in the 20th–28th percentile, the factor picture is weak across the board. Insider activity offers no relief — CFO Lance Tucker sold shares in April, February, and January, each time at prices well above the current $12.30 level.
Peer performance this week underscores how specific JACK's pain is. CBRL and CAKE both managed modest weekly gains, while TXRH and DRI were essentially flat. DIN slipped 2.4% — the only peer with a comparable weekly loss — but none matched JACK's 11.6% drawdown. The divergence between JACK and its casual and fast-casual peers reflects fundamental deterioration rather than sector-wide pressure.
With May 13 approaching, the key watch is whether the Q2 same-store sales trajectory shows any deceleration in the rate of decline — and whether management's second-half recovery narrative survives contact with the numbers.
See the live data behind this article on ORTEX.
Open JACK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
